secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2022-02-08T23:59:59+00:00
Accession:  0001628280-22-002018
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics CMO H. Jeffrey Wilkins resigns; effective date TBD
---------------------------------------------------------------------

- Dr. Wilkins resigns as Chief Medical Officer effective upon a date to be agreed upon.
- He will assist in orderly transition of duties through the effective date.
- No replacement named in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828022002018/0001628280-22-002018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828022002018/avtx-20220202.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-002018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer